Uterine fibroids — Causes, impact, treatment, and lens to the African perspective
Frontiers in Pharmacology · 10.01.2023 · 13
DOI: 10.3389/fphar.2022.1045783 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 10.01.2023. Verfasst von Narvella Sefah und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Chicago, Chicago, United States. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Burroughs Wellcome Fund.
Abstract (Originalsprache)
Leiomyomas, or uterine fibroids as they are commonly known, are mostly seen in women of reproductive age. However, they can go undetected in most women, and approximately 25% of women show clinical symptoms. Although fibroids are a global burden impacting 80% of premenopausal women, they are more prevalent among Black women than among women of other races. Based on clinical diagnosis, the estimated cumulative incidence of fibroids in women ≤50 years old is significantly higher for black (>80%) versus white women (∼70%). The cause of leiomyomas is not clearly known, but studies have shown evidence of factors that drive the development or exacerbation of the disease. Evidence has linked risk factors such as lifestyle, age, environment, family history of uterine fibroids, and vitamin D deficiencies to an increased risk of uterine fibroids, which impact women of African descent at higher rates. Treatments may be invasive, such as hysterectomy and myomectomy, or non-invasive, such as hormonal or non-hormonal therapies. These treatments are costly and tend to burden women who have the disease. Sub-Saharan Africa is known to have the largest population of black women, yet the majority of uterine fibroid studies do not include populations from the continent. Furthermore, the prevalence of the disease on the continent is not well determined. To effectively treat the disease, its drivers need to be understood, especially with regard to racial preferences. This paper aims to review the existing literature and build a case for conducting future research on African women.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Chicago, Chicago, United States.
- Fibroid Foundation Africa, Accra, Ghana.
- Sena Institute of Technology, Penyi, Ghana.
Förderung
- Burroughs Wellcome Fund
Zitieren
APA
Sefah, N., Ndebele, S., Prince, L., Korasare, E., Agbleke, M., Nkansah, A., Thompson, H., Al-Hendy, A., & Agbleke, A. A. (2023). Uterine fibroids — Causes, impact, treatment, and lens to the African perspective. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.1045783
Vancouver
Sefah N, Ndebele S, Prince L, Korasare E, Agbleke M, Nkansah A, et al. Uterine fibroids — Causes, impact, treatment, and lens to the African perspective. Frontiers in Pharmacology. 2023;13. doi:10.3389/fphar.2022.1045783
BibTeX
@article{Sefah2023,
author = {Sefah, Narvella and Ndebele, Sithembinkosi and Prince, Lillian and Korasare, Elizabeth and Agbleke, Michael and Nkansah, Annabella and Thompson, Humphrey and Al-Hendy, Ayman and Agbleke, Andrews Akwasi},
title = {Uterine fibroids — Causes, impact, treatment, and lens to the African perspective},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {13},
doi = {10.3389/fphar.2022.1045783}
}
EUVIMED